Kähkönen TE, Galabova G, Yang R, Xu Y, Wen J, Thormann M, Halleen JM 2025 OBP-004, a highly potent selective small-molecule dual inhibitor of CDK9/13 reduces bone metastatic growth, cancer-induced bone loss and bone pain of triple-negative breast cancer and castration-resistant prostate cancer in preclinical models. J Bone Miner Res 40 (Supplement 1):SAT-099. ASBMR Annual Meeting, September 5-8, 2025, Seattle, WA.
If you are interested to learn more,
see our services or contact us directly.
